Non–Small Cell Lung Cancer Coverage from Every Angle

Gérard Zalcman, MD, PhD, on Managing NSCLC With Nivolumab and Ipilimumab: Updated Findings on Optimal Length of Treatment

Posted: Thursday, September 15, 2022

Gérard Zalcman, MD, PhD, of France’s Bichat-Claude Bernard Hospital, Assistance Publique–Hôpitaux de Paris, discusses findings on the merits of a shorter or longer course of treatment with nivolumab plus ipilimumab in patients with advanced non–small cell lung cancer (NSCLC).

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.